Drug intelligence / Profile preview

225Ac-A9-0941

Development stage: Preclinical
Lead developer: Alpha-9 Oncology
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

225Ac-A9-0941 is a therapeutic radiopharmaceutical being developed by Alpha-9 Oncology for the treatment of solid tumors, specifically pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer. The drug consists of the alpha-emitting radioisotope Actinium-225 (^225Ac) conjugated to a proprietary targeting ligand, A9-0941, which is directed against an undisclosed target referred to as the "Program 2 target." By binding to this specific antigen on cancer cells, the agent delivers high-energy alpha particles that cause lethal double-stranded DNA breaks, leading to localized tumor cell death while sparing surrounding healthy tissue. As of August 2026, the program is in the IND-enabling stage of development.

Beyond the preview

Go deeper on 225Ac-A9-0941.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 225Ac-A9-0941.

Explore the full profile